1. Home
  2. KMB vs INSM Comparison

KMB vs INSM Comparison

Compare KMB & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kimberly-Clark Corporation

KMB

Kimberly-Clark Corporation

HOLD

Current Price

$103.09

Market Cap

35.5B

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$205.26

Market Cap

41.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KMB
INSM
Founded
1910
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Containers/Packaging
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.5B
41.2B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
KMB
INSM
Price
$103.09
$205.26
Analyst Decision
Hold
Strong Buy
Analyst Count
12
19
Target Price
$129.58
$178.71
AVG Volume (30 Days)
6.2M
2.7M
Earning Date
10-30-2025
10-30-2025
Dividend Yield
4.89%
N/A
EPS Growth
N/A
N/A
EPS
5.91
N/A
Revenue
$19,724,000,000.00
$447,022,000.00
Revenue This Year
N/A
$43.10
Revenue Next Year
$3.10
$128.25
P/E Ratio
$17.42
N/A
Revenue Growth
11.62
30.34
52 Week Low
$99.22
$60.40
52 Week High
$150.45
$212.75

Technical Indicators

Market Signals
Indicator
KMB
INSM
Relative Strength Index (RSI) 36.41 61.95
Support Level $101.76 $202.68
Resistance Level $110.03 $208.81
Average True Range (ATR) 2.14 6.31
MACD 0.54 -1.21
Stochastic Oscillator 15.11 59.86

Price Performance

Historical Comparison
KMB
INSM

About KMB Kimberly-Clark Corporation

With more than half of its sales from personal care and another third from consumer tissue products, Kimberly-Clark is a leading manufacturer in the tissue and hygiene realm. Its brand mix includes Huggies, PullUps, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates in the professional segment, partnering with businesses to provide safety and sanitary offerings for the workplace. Kimberly-Clark generates just over half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America. It intends to add Kenvue's consumer health portfolio to its mix in the second half of calendar year 2026.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Share on Social Networks: